Shots:

• The two companies collaborated to characterize the immune response to precision genetic therapeutics- utilizing Personalis’ advanced analytics
• The collaboration will combine Sarepta’s expertise in precision genetic medicine and Personalis’ advanced neoepitope prediction to characterize certain types of the immune response- benefitting patients with the rare disease
• The Personalis ImmunoID NeXT Platform is designed to adapt to the complex and evolving understanding of cancer- providing its customers with information on all the ~20-000 human genes- together with the immune system- from a single tissue sample

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter